We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$112M
Cap. Flow %
92.95%
Top 10 Hldgs %
42.01%
Holding
143
New
143
Increased
–
Reduced
–
Closed
–

Top Buys

1
HUM icon
Humana
HUM
+$10.2M
2
DVA icon
DaVita
DVA
+$6.77M
3
UNH icon
UnitedHealth
UNH
+$6.72M
4
PNTG icon
Pennant Group
PNTG
+$5.2M
5
CAH icon
Cardinal Health
CAH
+$3.95M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 67.79%
2 Financials 23.65%
3 Energy 1.95%
4 Materials 1.84%
5 Consumer Discretionary 1.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTTB icon
126
Q32 Bio
QTTB
$255M
$18.2K 0.02%
+6,019
New +$190K
RARE icon
127
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
$18.2K 0.02%
+158
New +$7.84K
CLDX icon
128
CALL
Celldex Therapeutics
CLDX
$2.77B
$15.3K 0.01%
+204
New +$5.54K
MRK icon
129
PUT
Merck
MRK
$315B
$14.2K 0.01%
+137
New +$14.1K
SMMT icon
130
CALL
Summit Therapeutics
SMMT
$10.7B
$12.2K 0.01%
+60
New +$1.16K
CAPR icon
131
PUT
Capricor Therapeutics
CAPR
$1.13B
$11.5K 0.01%
+177
New +$3.1K
KROS icon
132
CALL
Keros Therapeutics
KROS
$211M
$6.99K 0.01%
+354
New +$18.4K
KOD icon
133
CALL
Kodiak Sciences
KOD
$2.67B
$5.39K ﹤0.01%
+22
New +$126
TGTX icon
134
CALL
TG Therapeutics
TGTX
$8.4B
$5.12K ﹤0.01%
+295
New +$8.47K
VLY icon
135
PUT
Valley National Bancorp
VLY
$8.28B
$3.57K ﹤0.01%
+357
New +$3.46K
FLNA
136
PUT
Filana Therapeutics
FLNA
$51.2M
$2.86K ﹤0.01%
+24
New +$421
JANX icon
137
PUT
Janux Therapeutics
JANX
$992M
$2.78K ﹤0.01%
+53
New +$2.8K
QTTB icon
138
CALL
Q32 Bio
QTTB
$255M
$850 ﹤0.01%
+17
New +$537
PFE icon
139
CALL
Pfizer
PFE
$143B
$537 ﹤0.01%
+537
New +$14.6K
CORT icon
140
PUT
Corcept Therapeutics
CORT
$9.72B
$438 ﹤0.01%
+1
New +$52
MRNA icon
141
PUT
Moderna
MRNA
$24.5B
$268 ﹤0.01%
+268
New +$12.8K
ALXO icon
142
CALL
ALX Oncology
ALXO
$283M
$260 ﹤0.01%
+52
New +$80
LXRX icon
143
CALL
Lexicon Pharmaceuticals
LXRX
$1.06B
$135 ﹤0.01%
+3
New +$4
2 3 4 5
6

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for Persistent Asset Partners, which disclosed 143 positions worth $121M. Its ten largest holdings account for 42% of the portfolio.

Its largest position is Humana: 38,160 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, followed by Financials and Energy.

  • Persistent Asset Partners's largest Q4 2024 buy was Humana: 38,160 shares worth $11.2M.
  • Persistent Asset Partners's ten largest holdings make up 42% of its $121M portfolio in Q4 2024.
  • Persistent Asset Partners disclosed 143 positions in Q4 2024, its first 13F filing on record.

Based on Persistent Asset Partners's 13F filing for Q4 2024, filed 14 Feb 2025.